What was Citius Pharmaceuticals, Inc.'s revenue in Q1 FY2026?

Citius Pharmaceuticals, Inc. reported total revenue of $3.9M in Q1 FY2026.

What was Citius Pharmaceuticals, Inc.'s net profit in Q1 FY2026?

Citius Pharmaceuticals, Inc. reported net profit of $-9.4M in Q1 FY2026, a net margin of -238.2%.

What were Citius Pharmaceuticals, Inc.'s margins in Q1 FY2026?

Citius Pharmaceuticals, Inc. had gross margin of 80.0% and operating margin of -228.7% in Q1 FY2026.

What was Citius Pharmaceuticals, Inc.'s EPS in Q1 FY2026?

Citius Pharmaceuticals, Inc. reported diluted EPS of $-0.38 in Q1 FY2026.

Citius Pharmaceuticals, Inc.CTXREarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Deep Analysis

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.

Q1 2026

Revenue

$3.9M

Gross Profit

$3.2M

Operating Profit

$-9.0M

Net Profit

$-9.4M

Gross Margin

80.0%

Operating Margin

-228.7%

Net Margin

-238.2%

YoY Growth

N/A

EPS

$-0.38

Citius Pharmaceuticals, Inc. Q1 FY2026 Financial Summary

Citius Pharmaceuticals, Inc. reported revenue of $3.9M for Q1 FY2026, with a net profit of $-9.4M (up 8.6% YoY) (-238.2% margin). Cost of goods sold was $789.2K, operating expenses totaled $12.2M.

Key Financial Metrics

Total Revenue	$3.9M
Net Profit	$-9.4M
Gross Margin	80.0%
Operating Margin	-228.7%
Report Period	Q1 FY2026

Income Statement

	Q1 2026
Revenue	$3.9M
YoY Growth	N/A

Balance Sheet

	Q1 2026
Assets	$140.4M
Liabilities	$46.9M
Equity	$80.0M

Cash Flow

	Q1 2026
Operating CF	$-13.0M